Bold leadership elevates CIOs to the boardroom, according to Logicalis global study
50% of CIOs say their board expects them to deliver continuous innovation. 80% of CIOs…
Year: 2023
MFA Financial, Inc. Announces First Quarter Dividends on Series B Preferred Stock and Series C Preferred Stock
NEW YORK–(BUSINESS WIRE)–MFA Financial, Inc. (NYSE: MFA) (the “Company”) announced today that its Board of…
Data I/O Announces New SentriX Security Provisioning Services in Japan Through Noa Leading Co., Ltd
Noa Leading expands device programming services to include security provisioning with the SentriX Deployment Platform…
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
Pushing the Boundaries of DDR5 – CORSAIR® Launches New 48GB, 96GB and 192GB Memory Kits
MILPITAS, Calif.–(BUSINESS WIRE)–$CRSR–CORSAIR® (NASDAQ: CRSR), a world leader in enthusiast components for gamers, creators, and…
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
EDMONTON, Alberta, Feb. 21, 2023 (GLOBE NEWSWIRE) — Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”…
Neuronetics Sponsors the 5th International Brain Stimulation Conference
Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments…
Yield10 Bioscience Announces Key Advancements in the Development of Herbicide Tolerant Camelina Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market
–Second field trial confirms Camelina tolerance to over-the-top herbicide application –Greenhouse studies support proof-of-concept for…
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN) today announced that a…
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif.,…
Science 37 to Report Fourth Quarter 2022 Financial Results on March 6, 2023
RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
— Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial…
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®
FREMONT, CA, Feb. 21, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI) SOLANA BEACH, Calif. and…
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Mersana Therapeutics to Host Fourth Quarter and Year End 2022Â Conference Call on February 28, 2023
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage…
Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a…
Esperas Pharma, Inc. Announces Investment from TVM Life Science Innovation I and The Fonds de solidarité FTQ
MONTRÉAL, Feb. 21, 2023 (GLOBE NEWSWIRE) — Esperas Pharma, Inc. (“Esperas”), a company based in…
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the…